Oncogene addiction: setting the stage for molecularly targeted cancer therapy

Sreenath V. Sharma and Jeffrey Settleman

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA

In pugilistic parlance, the one-two punch is a devastating combination of blows, with the first punch setting the stage and the second delivering the knock-out. This analogy can be extended to molecularly targeted cancer therapies, with oncogene addiction serving to set the stage for tumor cell killing by a targeted therapeutic agent. While in vitro and in vivo examples abound documenting the existence of this phenomenon, the mechanistic underpinnings that govern oncogene addiction are just beginning to emerge. Our current inability to fully exploit this weakness of cancer cells stems from an incomplete understanding of oncogene addiction, which nonetheless represents one of the rare chinks in the formidable armor of cancer cells.

‘Oncogene addiction’: defining the term

Cancer is, an old adage goes, actually a hundred diseases masquerading as one. In our fight against this dreaded disease, casualties abound and successes are few and far between. Given the bewildering diversity of causality, it is gratifying to realize that painstaking investigation over the past 50 years has highlighted some common themes in the genesis and progression of cancer (Hana\-han and Weinberg 2000). These commonalities offer a glimmer of hope that potential targets may exist within the cancer cell that can be exploited in combating these diseases. The first unifying theme is that cancer is caused by a handful of “rogue” corrupted cellular genes, designated oncogenes, that hijack the cell, causing it to survive indefinitely and proliferate aberrantly. The second unifying theme is that the genesis and progression of a tumor is governed by the activation of specific oncogenes and inactivation of tumor suppressor genes, and the stochastic accumulation of these genetic alterations progressively drives the evolution of cancer from a benign expansion of cells to an invasive and metastatic tumor. This is well illustrated by the example of colorectal cancer (Kin\zialer and Vogelstein 1996).

On the face of it, this would suggest that cancer is a “moving target” that may be impossible to destroy. However, recently, a third common theme has begun to emerge that offers cause for guarded optimism. This phenomenon, referred to as “oncogene addiction,” a term first coined in 2000 by Bernard Weinstein, reveals a possible “Achilles’ heel” within the cancer cell that can be exploited therapeutically (Weinstein 2000, 2002; Weinstein and Joe 2006). In its simplest embodiment, oncogene addiction refers to the curious observation that a tumor cell, despite its plethora of genetic alterations, can seemingly exhibit dependence on a single oncogenic pathway or protein for its sustained proliferation and/or survival. At first glance, the fact that a tumor cell can exhibit dependency on a single protein that contributed to the malignant phenotype at some point in its history may seem to be trivial. However, the fact that inactivating the normal counterpart of such oncogenic proteins in normal tissues is often tolerated without obvious consequence highlights the unique state of addiction that appears to arise in cancer. A profound implication of this hypothesis is that switching off this crucial pathway upon which cancer cells have become dependent should have devastating effects on the cancer cell while sparing normal cells that are not similarly addicted. This, of course, is the discriminating activity required for any effective cancer therapeutic.

Models of oncogene addiction

Long before its articulation in 2000, hindsight reveals that several experimental findings reported in the literature could be explained by invoking oncogene addiction. These originate from a variety of settings, including human cancer cell lines, mouse tumor models, and clinical cancer studies (Table 1). In retrospect, the earliest evidence of oncogene addiction can be traced back to studies using human tumor-derived cell lines. That such a phenomenon can be observed in cell lines at all is remarkable in and of itself, since cell lines, which are often maintained in culture for prolonged periods, presumably accrue genetic alterations and undergo genetic drift over time, resulting from the genomic instability inherent in cancer. Moreover, cell lines are subject to the artificial pressures imposed by growth under nonphysiological conditions. Despite such pressures and the collateral...
<table>
<thead>
<tr>
<th>Oncogene</th>
<th>Cancer</th>
<th>Cell lines</th>
<th>Mouse models</th>
<th>Clinical (approved)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HER2</td>
<td>Breast, ovarian, NSCLC</td>
<td>Ab [Hudziak et al. 1989]</td>
<td>RI [Brysch et al. 1994; Colomer et al. 1994]</td>
<td>Gefitinib/Iressa (NSCLC); Erlotinib/Tarceva [NSCLC, pancreatic cancer]; Cetuximab/Erbilux (head and neck, colorectal cancer); Pantitumumab/ Vectibix (colorectal cancer)</td>
</tr>
<tr>
<td>BRAF</td>
<td>Melanoma, thyroid, colorectal</td>
<td>RI [Hingorani et al. 2003; Sumimoto et al. 2004]</td>
<td>SMI [Karasarides et al. 2004; Sharma et al. 2005]</td>
<td>Imatinib/Gleevec [Ph* CML, Ph* ALL]</td>
</tr>
<tr>
<td>EGFR</td>
<td>NSCLC, glioblastoma, colon, pancreas</td>
<td>RI [Yamazaki et al. 1998; Halatsch et al. 2000; Sordella et al. 2004]</td>
<td>SMI [Ji et al. 2006a,b; Politi et al. 2006]</td>
<td>Imatinib/Gleevec [GIST]; Sunitinib/Sutent [GIST, Renal cell carcinoma]; Imatinib/Gleevec [GIST]</td>
</tr>
<tr>
<td>KIT</td>
<td>GIST</td>
<td>SMI [Tuveson et al. 2001; Prenen et al. 2006]</td>
<td>SMI [Decaudin et al. 2005; Garton et al. 2006]</td>
<td></td>
</tr>
<tr>
<td>VEGF</td>
<td>Tumor angiogenesis</td>
<td>Ab [Kim et al. 1993; Kondo et al. 1993]; SMI [Sola et al. 1995] RI [Saleh et al. 1996; Cheng et al. 1996]</td>
<td>Bevacizumab/Avastin (Metastatic, colorectal cancer); Sunitinib/ Sutent [GIST, Renal cell carcinoma]; Sorafenib/ Nexavar [Renal cell carcinoma]</td>
<td></td>
</tr>
</tbody>
</table>

(RI) RNA interference; (IE) inducible expression; (SMI) small-molecule inhibitors; (Ab) antibody; (DN) dominant negative.
mutations, many human tumor cell lines appear to retain dependency on the very same activated oncogenes as the tumor from which they were derived, and faithfully undergo either proliferative arrest, senescence, differentiation, or apoptosis upon inactivation of the misregulated oncogene. Furthermore, the genetic lesion that renders a tumor susceptible to a targeted inhibitor, if present in a cell line, often confers the same degree of sensitivity to that inhibitor. The demonstration of oncogene addiction in tumor cell lines strongly implicates a cancer cell-autonomous response to acute oncprotein inactivation, at least in some cases, which is largely independent of external factors such as stromal interactions. This further suggests that oncogene addiction is a trait that must be beneficial—if not essential—to the survival of the tumor cell, and is therefore maintained in the face of genetic drift in culture. In fact, it is probably not unreasonable to postulate that most, if not all, dramatic responses of “tumor shrinkage” following molecularly targeted therapy result from the acute inactivation of an activated oncprotein upon which the tumor cells became dependent.

**MYC** was among the first oncogenes to be identified, and its deregulated expression is widespread in human cancer [Vita and Henriksson 2006]. Disruption of **MYC** by antisense RNA in human tumor-derived cell lines, leading to inhibition of proliferation and induction of differentiation [Yokoyama and Imamoto 1987; Loke et al. 1988], serves as one of the first experimental demonstrations of oncogene addiction, even though the term itself did not come into existence until more than a decade later. The fact that acute inactivation of **MYC** in conditional mouse models of **MYC**-induced lymphoma and leukemia leads to the rapid induction of apoptosis and/or cellular senescence [Felsher and Bishop 1999; Arvanitis and Felsher 2006; Wu et al. 2007], albeit in a context-dependent manner [Beer et al. 2004; Boxer et al. 2004], supports a role for deregulated **MYC** in oncogene addiction. This experimental finding was among the first to be directly attributed to oncogene addiction [Jain et al. 2002; Weinstein 2002].

Mutations in **RAS** genes (**H-RAS**, **Ki-RAS**, and **N-RAS**) occur in 30% of human cancers, and transgenic mouse models support their causative role in neoplasia [Schubbert et al. 2007]. The use of inducible **H-RAS** and **Ki-RAS** oncogenes in mouse tumor models of melanoma and lung adenocarcinoma, respectively, has provided evidence that addiction to the **RAS** oncprotein results in tumor cell apoptosis following the acute inactivation of the **RAS** oncprotein [Chin et al. 1999; Fisher et al. 2001]. These observations are supported by similar studies using human tumor-derived cell lines [see Table 1], highlighting the significance of the **RAS** signaling pathway as a therapeutic opportunity.

While tumor dependency on the well-studied “classical” oncogenes, such as **MYC** and **RAS**, has now been demonstrated in a variety of experimental models, more recent studies have begun to reveal additional classes of genes that may also confer a state of dependency in cancers when dysregulated. For example, oncogenic micro-RNAs (“oncomirs”) have emerged recently as important players in cancer [Esquela-Kerscher and Slack 2006]. The apparent role of oncomirs in oncogene addiction is highlighted by the demonstration that antisense inhibition of **miR-17-5p** and **miR-20a** leads to apoptosis of lung cancer cells overexpressing the microRNA **miR-17-92** [Matsubara et al. 2007]. Thus, “oncomir addiction” may be yet another manifestation of oncogene addiction. However, the potentially pleiotropic action of oncomirs may prove to substantially limit the therapeutic opportunity that such addiction might otherwise present.

**Activated kinases: the “Achilles’ heel” of many cancers**

Protein kinases appear to represent particularly important targets for cancer therapy. The fact that they are frequently activated by mutation and/or gene amplification highlights their role in a variety of human cancers and, consequently, they feature prominently in the cancer drug development pipelines of many biotechnology and pharmaceutical companies. The clinical success of the multikinase inhibitor imatinib in treating chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) essentially led to a paradigm shift in cancer treatment strategies, and represented some of the first examples of oncogene addiction in the context of cancer therapy. The **ABL** and platelet-derived growth factor receptor (**PDGFR**) tyrosine kinases, which are targets of imatinib, are often activated by chromosomal translocations (**BCR-ABL**, **TEL-ABL**, **TEL-PDGFR**). Tumor cell lines harboring these activated **ABL** and **PDGFR** alleles become addicted to them for their survival and, consequently, undergo apoptosis following acute inactivation of the **ABL** or **PDGFR** oncproteins using RNA interference (RNAi) [Skorski et al. 1994; Smetsers et al. 1994] or targeted inhibitors such as imatinib and **SKI-606** [Druker et al. 1996, 2001; Carroll et al. 1997; Deininger et al. 1997; Golas et al. 2003]. Imatinib, which also targets the **KIT** receptor tyrosine kinase, causes apoptosis of small cell lung cancer (**SCLC**) cell lines addicted to the autocrine loop created by the expression of **KIT** as well as its ligand, stem cell factor (**SCF**) in these cells in culture or grown as xenografts [Kryskal et al. 2000; Deacund et al. 2005]. In addition, mutations in **KIT**, frequently encountered in **GIST** [Hirota et al. 1998] renders these cells addicted to the **KIT** oncprotein, and its inactivation by imatinib, **SU11248**/**Sunitinib** or **OSI-930** leads to apoptosis of the tumor cells [Tuveson et al. 2001; Garton et al. 2006; Prenen et al. 2006]. Interestingly, 35% of **GISTs** lacking **KIT** mutations harbor mutations in **PDGFRα** [Heinrich et al. 2003b], and these tumor cells, which appear to be dependent on activated **PDGFRα**, undergo apoptosis following imatinib treatment [Heinrich et al. 2003a]. The autocrine loop involving **PDGFR** has also been implicated in the etiology of gliomas [Nister et al. 1991; Fleming et al. 1992], and addiction to this pathway is suggested by the tumor cell inhibition seen upon treatment with small molecule inhibitors such as **SU101/leflunomide**, **SU6668** and **STI571/Imatinib**, and **GF1-111** [Shawver et al. 1997; Blaskovich et al. 2000; Kilic et al. 2002].
The clinical activity of imatinib in multiple disease settings, together with numerous cancer cell line studies demonstrating an apoptotic response to drug treatment, suggests that clinical responses are likely to reflect a cancer cell-autonomous dependency on specific activated kinases for their survival.

Oncogene addiction may also contribute to the clinical success of agents that target the ErB family receptor, ErbB2/HER2. The erbB2/HER2 oncogene is amplified in 25%–30% of breast cancers (Berger et al. 1988; Guerin et al. 1988), suggesting that these tumors may be addicted to HER2. Consistent with such dependency, breast cancer cells in culture or grown as xenografts in nude mice are preferentially growth inhibited by HER2-specific antibodies (Hudziak et al. 1989; Shepard et al. 1991; Ohnishi et al. 1995; Tokuda et al. 1996), antisense oligonucleotides [Brysch et al. 1994; Colomer et al. 1994] and HER2-targeted small molecule inhibitors such as lapatinib, HKI-272, and BMS-599626 [Xia et al. 2002; Rabin-Dran et al. 2004; Wong et al. 2006]. These findings formed the basis for the treatment of patients with HER2-amplified metastatic breast cancer with the HER2 targeted antibodies, Trastuzumab/Herceptin and Pertuzumab [Hudis 2007].

The use of selective epidermal growth factor receptor (EGFR) kinase inhibitors in lung cancer treatment represents yet another example of oncogene addiction that has yielded clinical success in a subset of patients with advanced disease that are otherwise refractory to conventional chemotherapy treatment. Mutations in the kinase domain of EGFR are found in a subset (10%–20%) of non-small cell lung cancers [NSCLC], and dramatic clinical responses to treatment with the small molecule EGFR kinase inhibitors gefitinib and erlotinib have been well correlated with such mutations [Lynch et al. 2004; Paez et al. 2004; Pao et al. 2004; Sharma et al. 2007]. Glioblastomas frequently harbor EGFR gene amplification [Libermann et al. 1985; Wong et al. 1987] as well as EGFR deletion mutations in the ligand-binding domain [EGFRvIII] [Yamazaki et al. 1990; Nishikawa et al. 1994], and these tumors appear to be similarly addicted to EGFR activating mutations. A role for oncogene addiction in these clinical settings is supported by in vitro studies using tumor cell lines as well as in transgenic mouse models (see Table 1).

In addition to the clinical successes that have been observed with a few inhibitors of kinases to which tumor cells have become addicted, there is accumulating preclinical data suggesting that this phenomenon may be applicable to a large number of other kinases, underscoring the potential broad importance of oncogene addiction in molecularly targeted cancer therapy. For example, one of the seminal findings of the cancer genome sequencing projects was the identification of recurrent activating BRAF kinase mutations [predominantly V600E] in 70% of melanomas, 40% of thyroid cancers, and 20% of colorectal cancers [Davies et al. 2002]. The fact that inhibition of oncopinic BRAF V600E by RNAi [Hingorani et al. 2003; Sumimoto et al. 2004] or small molecule inhibitors of the BRAF downstream target MEK, such as CI-1040 and its derivative PD0325901 [Solit et al. 2006] results in growth arrest followed by apoptosis of cancer cells harboring onogenic BRAF mutations, and suggests that such tumors are BRAF-addicted. Similarly, BRAF inhibitors such as Sorafenib and BAY 43-9006 [Karasarides et al. 2004; Sharma et al. 2005] cause growth arrest and apoptosis of human tumor cell lines and xenografts harboring the onogenic variant of BRAF.

Accumulating data derived largely from cancer genome resequencing and comparative genome hybridization studies have also highlighted the likely role of “kinase addiction” in a variety of human cancers. For example, MET gene amplifications, as well as mutations and aberrant expression of the HGF/MET signaling pathway have been observed in a significant fraction of gastric cancers, lung cancers, glioblastomas, colorectal cancers, esophageal cancers, and prostate cancers. The fibroblast growth factor receptor 3 [FGFR3] is activated in 15% of multiple myelomas by a chromosomal translocation t(4;14)[p16.3;q32.3] [Chesi et al. 1997]. A chromosomal translocation that results in the generation of a fusion transcript between nucleoplasmin [NPM] and anaplastic lymphoma kinase [ALK] similarly leads to kinase activation in ~60% of Anaplastic Large Cell Lymphomas [ALCL] [Morris et al. 1994]. Recent studies implicating the EML4-ALK fusion oncoprotein in the etiology of NSCLC indicate another potential setting for ALK addiction in human cancer [Soda et al. 2007]. Aurora kinases are frequently amplified in a diverse array of human cancers such as leukemias and colon and pancreatic tumors [Marumoto et al. 2005]. Lastly, the RET oncogene is frequently mutated in medulillary thyroid carcinomas and a subset of papillary thyroid cancers [Drosten and Putzer 2006; Kondo et al. 2006]. Underscoring the importance of oncogene addiction is the fact that in all the abovementioned cases [BRAF, MET, FGFR3, ALK, Aurora kinase, and RET], acute inactivation of the mutated kinase by a variety of methods in different systems typically results in growth inhibition or tumor cell death (see Table 1). These examples also highlight the fact that mutationally activated oncogenes, especially kinases, appear to represent cancer culprits that frequently contribute to a state of oncogene dependency.

Tumor suppressor restoration: the flip side of oncogene addiction

Just as acute inactivation of addicting oncoproteins frequently leads to cancer cell death, recent evidence points to similar outcomes engendered by the reintroduction of wild-type versions of tumor suppressor genes that are frequently inactivated in cancer cells [Table 2]. This phenomenon, referred to as “tumor suppressor hypersensitivity” [Weinstein 2002], may represent another dimension of oncogene addiction, since it is likely that in the establishment of the oncogene addicted state, a prerequisite may involve the removal of support systems such as tumor suppressors that buttress normal cell survival.
Table 2. Examples of tumor suppressor genes that confer oncogene addiction

<table>
<thead>
<tr>
<th>Tumor suppressor</th>
<th>Cancer</th>
<th>Oncogene addiction and oncogenic&lt;br&gt;Cell lines</th>
<th>Mouse models</th>
</tr>
</thead>
<tbody>
<tr>
<td>LKB1</td>
<td>Peutz-Jeghers syndrome</td>
<td>Qanungo et al. 2003</td>
<td></td>
</tr>
<tr>
<td>DLC-1</td>
<td>Hepatocellular carcinoma</td>
<td>Zhou et al. 2004</td>
<td></td>
</tr>
<tr>
<td>FHTI</td>
<td>Lung, cervical, breast</td>
<td>Roz et al. 2002; Sevignani et al. 2003</td>
<td>Sevignani et al. 2003; Pichiorri et al. 2006</td>
</tr>
<tr>
<td>ARLTS1</td>
<td>Breast, ovarian, lung, familial cancer</td>
<td>Petrozza et al. 2006</td>
<td>Petrozza et al. 2006</td>
</tr>
<tr>
<td>IRF-1</td>
<td>Leukemia</td>
<td>Kim et al. 2004; Bouker et al. 2005; Iliopoulos et al. 2007</td>
<td>Kim et al. 2004; Watson et al. 2006</td>
</tr>
<tr>
<td>WWOX</td>
<td>Lung, breast, prostate</td>
<td>Fabbrini et al. 2005; Qin et al. 2006; Iliopoulos et al. 2007</td>
<td>Fabbrini et al. 2005; Qin et al. 2006; Iliopoulos et al. 2007</td>
</tr>
<tr>
<td>TESTIN</td>
<td>Breast, uterine</td>
<td>Sarti et al. 2005</td>
<td></td>
</tr>
<tr>
<td>PTEN</td>
<td>Gliomas</td>
<td>Tian et al. 1999</td>
<td></td>
</tr>
</tbody>
</table>

Nowhere is this phenomenon more evident than in the case of the p53 tumor suppressor pathway, which is inactivated in most human cancers (Soussi 2007; Vousden and Lane 2007). Consistent with “addiction to lack of tumor suppressor genes,” reintroduction of wild-type p53 into cancer cells harboring mutant p53 or p53-deficient cancer cells (Adachi et al. 1996; Gomez-Manzano et al. 1996; Vater et al. 1996), or stabilization of wild-type p53 by small molecule inhibitors [Hietanen et al. 2000], or even “conversion” of mutant p53 to a form structurally resembling wild-type p53 (Bykov et al. 2002), can result in cancer cell ablation or senescence in a context-specific manner. These findings formed the basis for the proposal that systemic reintroduction of p53 in cancer patients could result in selective toxicity to tumor cells [McCormick 2001]. While translation of this concept to cancer patients remains to be realized, recent studies in transgenic mice provide proof of concept and lend validity to p53 restoration as a cancer therapeutic (Reddy and Kaelin 2002). Similar studies suggest that signaling network abnormalities may lead to extragenic suppression and synthetic lethal interactions with activated oncogenes (Reddy and Kaelin 2002; Kaelin 2005). Thus, two genes are synthetically lethal if inactivation of either gene, but not both, is compatible with cell survival. Thus, in the cancer cell, the activating oncogene is believed to be in a synthetic lethal relationship with another gene that is inactivated in the cancer cell. It follows that under these circumstances elimination of the oncogene would lead to the death of the cancer cell but would not similarly affect other normal cells in which such a synthetic lethal relationship does not exist. In his original proposal, Bernard Weinstein postulated that “because of their bizarre circuitry, cancer cells suffer from ‘gene addiction’ and ‘gene hypersensitivity’ disorders that might be exploited in both cancer prevention and chemotherapy” [Weinstein 2000]. While each of these hypotheses provides a theoretical explanation for the response of the addicted cancer cell to acute inactivation of the adding oncogene, leading to the collapse of the “molecular house of cards” in the cancer cell, experimental evidence to support them is largely lacking.

We recently proposed a model referred to as “oncogenic shock” to account for the observed apoptotic outcome resulting from the acute inactivation of oncogenes in addicted cancer cells (Sharma et al. 2006a,b; Sharma and Settleman 2006). According to this model, proapoptotic as well as prosurvival signals are both outputs emanating from the same addiction oncogene, and the differential decay rates associated with these two broad classes of signals following oncogene inactivation, leads to a signal imbalance that contributes to cell death [Fig. 1]. Indeed, as detailed in the following section, evidence supporting such a duality of signaling output from many activated oncogenes, including RAS, MYC, SRC, and EGFR, has been well established. Moreover, numerous studies indicate that tumors often exhibit enhanced apoptotic activity, and it has been suggested that tumor cells may be teetering on the threshold of an apoptotic outcome.

The molecular basis of oncogene addiction

Various hypotheses have been proposed to account for the phenomenon of oncogene addiction. In the genetic streamlining hypothesis [Mills et al. 2001; Kamb 2003], natural selection, fueled by genomic instability of cancer cells, is believed to result in the deterioration, through disuse, of certain signaling pathways operational in normal cells, and the emergence and pre-eminence of the oncogenic signaling pathway. Similarly, it has been suggested that signaling network abnormalities may lead to extragenic suppression and synthetic lethal interactions with activated oncogenes [Reddy and Kaelin 2002; Kaelin 2005].

The molecular basis of oncogene addiction

Various hypotheses have been proposed to account for the phenomenon of oncogene addiction. In the genetic streamlining hypothesis [Mills et al. 2001; Kamb 2003], natural selection, fueled by genomic instability of cancer cells, is believed to result in the deterioration, through disuse, of certain signaling pathways operational in normal cells, and the emergence and pre-eminence of the oncogenic signaling pathway. Similarly, it has been suggested that signaling network abnormalities may lead to extragenic suppression and synthetic lethal interactions with activated oncogenes [Reddy and Kaelin 2002; Kaelin 2005]. Thus, two genes are synthetically lethal if inactivation of either gene, but not both, is compatible with cell survival. Thus, in the cancer cell, the activating oncogene is believed to be in a synthetic lethal relationship with another gene that is inactivated in the cancer cell. It follows that under these circumstances elimination of the oncogene would lead to the death of the cancer cell but would not similarly affect other normal cells in which such a synthetic lethal relationship does not exist. In his original proposal, Bernard Weinstein postulated that “because of their bizarre circuitry, cancer cells suffer from ‘gene addiction’ and ‘gene hypersensitivity’ disorders that might be exploited in both cancer prevention and chemotherapy” [Weinstein 2000]. While each of these hypotheses provides a theoretical explanation for the response of the addicted cancer cell to acute inactivation of the adding oncogene, leading to the collapse of the “molecular house of cards” in the cancer cell, experimental evidence to support them is largely lacking.

We recently proposed a model referred to as “oncogenic shock” to account for the observed apoptotic outcome resulting from the acute inactivation of oncogenes in addicted cancer cells (Sharma et al. 2006a,b; Sharma and Settleman 2006). According to this model, proapoptotic as well as prosurvival signals are both outputs emanating from the same addiction oncogene, and the differential decay rates associated with these two broad classes of signals following oncogene inactivation, leads to a signal imbalance that contributes to cell death [Fig. 1]. Indeed, as detailed in the following section, evidence supporting such a duality of signaling output from many activated oncogenes, including RAS, MYC, SRC, and EGFR, has been well established. Moreover, numerous studies indicate that tumors often exhibit enhanced apoptotic activity, and it has been suggested that tumor cells may be teetering on the threshold of an apoptotic outcome.
Proapoptotic roles are only just beginning to be appreciated. The oncoproteins has long been recognized, their proapoptotic signals. While the prosurvival function of oncoproteins simultaneously generate both prosurvival and proapoptotic outputs. Even in this oncoprotein-addicted state, the survival outputs from the actively signaling oncoprotein predominate, thereby keeping the oncoprotein-induced death signal in check. Upon acute inactivation of the oncoprotein, “oncogenic shock” results in differential signal attenuation, associated with the rapid attenuation of oncoprotein-generated prosurvival signals, whereas the oncoprotein-induced proapoptotic signals linger sufficiently long such that the cell becomes committed to an apoptotic death. During this vulnerable window of time [indicated by the blue shaded box], the longer-lived proapoptotic signals gain the upper hand and cause the cells to irreversibly undergo apoptosis.

Janus faces of oncogenes: Dr. Jekyll and Mr. Hyde

Implicit in the oncogenic shock, genetic streamlining/signaling network suppression, and synthetic lethality models is the paradoxical requirement that activated oncoproteins simultaneously generate both prosurvival and proapoptotic signals. While the prosurvival function of oncoproteins has long been recognized, their proapoptotic roles are only just beginning to be appreciated. The earliest evidence of such antagonistic duality in oncoprotein function came from studies of the MYC oncogene [Evan et al. 1994; Harrington et al. 1994b; Hueber and Evan 1998]. The proapoptotic function of overexpressed MYC was manifest under conditions of reduced serum concentration [Evan et al. 1992], a common experimental treatment that, in retrospect, probably limited all other survival inputs and served to focus oncogene addiction/dependency on one critical survival pathway, thereby uncovering the proapoptotic function of oncoproteins operating along that pathway. This inference is supported by subsequent studies demonstrating that MYC-induced apoptosis is inhibited by specific cyтокines [Harrington et al. 1994a] via the activation the PI-3 kinase/Akt pathway [Kauffmann-Zeh et al. 1997]. MYC-induced cell death is mediated by apoptosis, as evidenced by its inhibition by BCL-2 [Bissonnette et al. 1992]. Moreover, MYC-induced apoptosis plays a physiological role in antigen-induced negative selection of developing T cells [Shi et al. 1992] suggesting that it is not a cell culture oddity. The proapoptotic function of c-MYC, and its negative regulation by BCL-2, have also been demonstrated in vivo using mouse models [Alarcon et al. 1996]. Such antagonistic functional duality is an essential feature of oncoproteins that engender addiction.

The transcription factor E2F1 is an established prosurvival molecule that also exhibits proapoptotic activity that is dependent on the presence of wild-type p53/p73 and the absence of the pRb tumor suppressor [Qin et al. 1994; Wu and Levine 1994; Irwin et al. 2000]. E2F1-mediated apoptosis results from the premature entry of cells into the S phase of the cell cycle followed by apoptotic cell death [Shan and Lee 1994; Kowalik et al. 1995], which requires its binding partner DP-1 [Hiebert et al. 1995; Shan et al. 1996], and is antagonized by the p53 regulator, MDM2 [Kowalik et al. 1998; Loughran and La Thangue 2000]. Overexpressed as well as endogenous E2F1 participates in apoptosis, as demonstrated by suppression of apoptosis, and S-phase entry defects in E2F1-deficient mice [Tsai et al. 1998]. Thus, E2F1 exhibits dual “opposing” functions that are likely to be context-dependent in cancer cells.

Previous studies have shown similarly that the v-JUN oncprotein is proapoptotic in the absence of growth factors and, like MYC, requires BCL-2 for this activity [Frisch et al. 1996, Clark and Gillespie 1997; MacLaren et al. 2000]. Similar context-dependent dual opposing functions are exhibited by the JUN kinase, [JNK], and stress activated protein kinase, p38 [Xia et al. 1995]. A proapoptotic function has also been reported for c-FOS [Preston et al. 1996, 2000] and this activity plays an important role in normal mouse development [Smyne et al. 1993]. In addition to the oncogenic transcription factors discussed thus far, proapoptotic roles have also been uncovered for cytoplasmic oncoproteins such as RAF and RAS. Sustained high-level expression of oncogenic RAF in primary human cells leads to cell cycle arrest and premature senescence through the induction of the cyclin-dependent kinase inhibitors p16(Ink4a) and/or p21(Cip1) [Woods et al. 1997; Zhu et al. 1998; Fanton et al. 2001]. The pre-eminence of RAS oncogenes in human cancer might at first glance appear to be somewhat at odds with a proapoptotic role for this oncprotein. Nonetheless, the proapoptotic functions of activated RAS and MYC are the best characterized among the numerous identified oncoproteins [Arbor 1999]. The first inking for a proapoptotic role for oncogenic RAS emerged from experiments described more than 20 years ago, and subsequent studies demonstrated that this activity required PKK, BCL-2, p53, p16INK4a, p19ARF, NF-kB, and occurred in a caspase-independent manner [Chen and Faller 1995; Rak et al. 1995b; Wang et al. 1995; Miranda et al. 1996; Mayo et al. 1997; Serrano et al. 1997; Chen et...
Oncogenic tyrosine kinases such as SRC, ABL, and EGFR also demonstrate a dual pro- and anti-death function, although this has not been as well characterized in the two latter cases. Unlike the other oncoproteins described to this point, the proapoptotic function of oncprotein tyrosine kinases is manifested primarily upon acute inactivation. Like MYC, the proapoptotic functions of v-SRC are revealed under low serum conditions and can be abrogated by the provision of serum growth factors or BCL-2 [Johnson et al. 2000; Webb et al. 2000; Sharma et al. 2006b]. The primary survival pathways activated by v-SRC are the MEK/ERK and the PI-3 kinase/AKT pathways, and apoptosis following acute inactivation of the oncprotein leads to attenuation of these pathways and the activation of p38 MAP (mitogen-activated protein) kinase proapoptotic pathways immediately preceding cell death [Johnson et al. 2000; Sharma et al. 2006b]. A similar response is seen following acute inactivation of the BCR-ABL and mutationally activated EGFR kinases [Sharma et al. 2006b]. This antagonistic duality even extends to viral oncoproteins such as adenovirus E1A (White and Stillman 1987) and papillomavirus E7 [Liu et al. 2000]. Thus, it is quite possible that many if not all oncoproteins are similarly endowed with the dual “life and death” capability. The challenge for investigators lies in our ability to establish the particular context that will enable these opposing roles to be uncovered. The fact that cancer cells exhibit remarkably high levels of spontaneous cell death [in addition to their enhanced proliferative capacity] is a testament to the potential universality of this phenomenon in cancer. In this regard, it is very likely that in the context of activated oncogenes, cell proliferation, and apoptosis are tightly coupled, thereby providing a potential “Achilles’ heel” of the cancer cell that can be exploited therapeutically [Evan and Littlewood 1998].

Oncogene addiction and differential signal decay

An important and therapeutically relevant feature of oncogene addiction relates to the tumor cell-specific induction of apoptosis, which begs the question: Why does inactivation of the corresponding proto-oncogenes not lead to a similar outcome in normal cells? This question is particularly germane in light of the fact that most clinically used targeted kinase inhibitors, for example, are not completely specific for oncogenic proteins, and, in all likelihood, also inhibit their normal counterparts. Although activating EGFR mutants are biochemically more sensitive to EGFR inhibition [Mulloy et al. 2007], wild-type and mutant EGFR proteins are both efficiently inhibited at clinically relevant drug concentrations, suggesting that this differential biochemical sensitivity is unlikely to explain the clinical responses in EGFR mutant tumors. While a definitive answer to this question awaits further analysis, one possibility is that the attenuation of signals emanating from an actively signaling kinase, for example, is a well-orchestrated process in which the apoptotic output is balanced with a sufficient anti-apoptotic output. The excessive, and sometimes qualitatively altered signaling downstream from an activated oncoprotein, on the other hand, may result in disruption of a carefully orchestrated signal attenuation process that normally occurs in nonmalignant cells.

Alternatively, it is possible that the excessive apoptotic signals derived from activated oncoproteins in cancer cells shifts the “balance of power” such that the slightest disruption of survival signaling following oncoprotein inactivation rapidly leads to an apoptotic outcome. Thus, in a viable tumor cell, it is likely that prosurvival signals emanating from an active oncoprotein predominate and keep the proapoptotic signals “in check.” While excessive survival signals, as well as death signals, are probably being transduced within many cancer cells, the balance between these signals clearly favors the survival of the tumor cell. However, upon acute oncoprotein inactivation following exposure to an inhibitor of the addicting oncoprotein, prosurvival signals are observed to decay rapidly, while proapoptotic outputs, which appear to be longer lived, persist for many hours [Sharma et al. 2006b]. Thus, for a brief period of time following acute oncoprotein inactivation, a signaling imbalance results in the predominance of proapoptotic signals in the cell. This “differential signal decay” leading to a temporary predominance of proapoptotic outputs sets the apoptotic cascade in motion, thereby committing the cancer cell irrevocably to apoptosis [Fig. 1]. Such differential signal decay constitutes the essence of the oncogenic shock model and is equally consistent with genetic streamlining/signaling network suppression and synthetic lethality, although we hasten to add that rigorous proof of this mechanism remains to be established, and in this regard, these models are largely theoretical. Nevertheless, it is important to consider oncogene addiction and oncogenic shock as interdependent phenomena, with oncogene addiction describing the state of the cancer cell before the acute inactivation of the oncoprotein and oncogenic shock describing the potential consequence of acute inactivation of the addicting oncoprotein.

Factors influencing oncogene addiction

As described above, acute oncoprotein inactivation in cancer cells often results in apoptosis. Therefore, factors that influence apoptosis are likely to influence the response to oncoprotein inactivation in oncogene-addicted tumors. It has long been recognized that disregulated cell proliferation and suppression of apoptosis are hallmarks of cancer [Hanahan and Weinberg 2000; Evan and Vousden 2001; Green and Evan 2002; Lowe et al. 2004]. Indeed, cancer cells deploy a diverse array of mechanisms to avoid apoptosis, such as inhibition of cell death mediating proteins [Soengas et al. 2001; Lowe et al. 2004] and/or overexpression of cell death inhibitory proteins of the BCL-2 or IAP [inhibitors of apoptosis] family [Cory and Adams 2002; Salvesen and Duckett 2002; Danial and
Oncogene addiction

Korsmeyer 2004]. One such member of the IAP family, survivin, that is frequently expressed in human cancers provides a link between cell cycle progression and apoptosis by inhibiting the proapoptotic protein Caspase-3 [Li et al. 1998; Li et al. 1999]. Similarly, the transcription regulator Id3 closely couples G1-stage cell cycle progression and apoptosis [Norton and Atherton 1998; Sikder et al. 2003].

The genetic constitution of the tumor cell, aside from a single addicting oncogene, will almost certainly influence the response to oncprotein inactivation. For example, mutations in the ARF/p53 pathway potently attenuate the proapoptotic and/or prosenescence properties of oncogenic BCR-ABL, and tumors harboring such mutations appear to be particularly resistant to imatinib [Williams et al. 2006, 2007]. This might help to explain the failure of targeted therapies in certain tumors despite the presence of activating mutations in oncogenes that might otherwise confer a state of addiction.

It is also important to consider that cancer cells are under the influence of signals both from within the cell, as well as from the external microenvironment in which they exist. The relationship of a tumor with its microenvironment is a highly complex and symbiotic one in which the tumor cells influence the microenvironment, which in turn influences the tumor by providing a niche for optimal tumor growth [Schors and Evan 2007]. Components of the microenvironment that exist in such a “give-and-take” relationship with the tumor include the extracellular matrix on which the tumors grow and the vasculature that nourishes and sustains them. Attracting the vasculature (angiogenesis) is particularly important in the transition of a benign tumor to malignancy, a phenomenon termed the “angiogenic switch” [Folkman and Hanahan 1991]. Addicting oncoproteins such as RAS and MYC have a propensity to turn on this angiogenic switch by inducing the expression of matrix metalloproteinases (MMP), especially MMP-9, [Bernhard et al. 1994] and inhibition of MMP-9 blocks the metastatic capability of such tumors [Hua and Muschel 1996]. Tumors harboring activated RAS are capable of activating the angiogenic switch by up-regulating vascular endothelial growth factor (VEGF) and MMP [Arbiser et al. 1997]. Similarly, EGF as well as activated EGFR, both, induce the expression of VEGF via PI3 kinase in glioblastomas [Goldman et al. 1993; Petit et al. 1997; Maity et al. 2001; Clarke et al. 2001; Casanova et al. 2002]. Consistent with this, dual inhibition of EGFR and VEGFR induces potent anti-tumor effects in mouse tumor models [Sini et al. 2005; Younes et al. 2006] and provides the rationale for ongoing clinical testing of several multitargeted kinase inhibitors such as ZD-6474, AEE 788, and XL647 [Sharma et al. 2007]. Oncogenic H-RAS or Ki-RAS as well as oncogenic SRC and RAF all up-regulate a variety of cytokines and growth factors that either directly or indirectly induce angiogenesis [Rak et al. 1995a]. Similarly, the MET receptor ligand, hepatocyte growth factor, also induces VEGFR expression, which may serve to increase tumor angiogenesis in MET-addicted tumors [Moriyama et al. 1998; Van Belle et al. 1998; Dong et al. 2001].

Another mechanism by which tumors might throw the angiogenic switch relates to the architecture of the tumor itself. The hypoxic interior of the tumor may be sufficient to trigger angiogenesis via the induction of hypoxia-inducible factors (HIFs), a family of proteins whose diverse targets include a multitude of proangiogenic mediators such as inducible nitric oxide synthase (iNOS), VEGF, EGF, PDGF, and basic FGF [Liao and Johnson 2007]. This interdependency of tumors with the vasculature forms the basis for anti-angiogenic therapy using agents such as bevacizumab [Avastin], a humanized monoclonal anti-vascular antibody targeting VEGF or small molecule inhibitors that target VEGF such as BAY-43-9006/Sorafenib, SU11248/Sunitinib [Kerbel 2006]. However, it should be noted that the clinical activity of VEGF-targeted drugs might simply reflect tumor “starvation,” as opposed to oncogene addiction. Furthermore, the contribution of the tumor environment to the state of oncogene dependency implicates tumor cell-nonautonomous mechanisms in at least some cases of oncogene addiction.

Clinical implications of oncogene addiction

The striking correlation between the presence of activating mutations and/or gene amplifications of the target kinases of several clinically effective inhibitors and the response to treatment with those inhibitors highlights the potential importance of oncogene addiction in molecularly targeted cancer therapy. Indeed, the dual survival-apoptosis signaling output from such kinases, as described above, appears to have provided an exploitable therapeutic opportunity in which the oncprotein can be essentially turned against the tumor cell by acutely disrupting the balance between these signals. Although this phenomenon has been limited thus far, in clinical settings, to a few of the known oncogenic kinases, including EGFR, HER2, BCR-ABL, PDGFR, and c-KIT, it is likely that efforts of the cancer genome sequencing projects currently underway will yield many additional candidate oncogenic kinases to which cancer cells potentially exhibit addiction, and may therefore constitute important targets for drug development. Along these lines, it is notable that preclinical cell-based studies suggest that oncogene addiction may also provide a therapeutic opportunity in the setting of gastric cancers and NSCLCs with an amplified MET kinase gene, and melanomas, thyroid, and colorectal cancers that harbor the recurrent BRAF mutation V600E, and clinical studies are underway to examine the efficacy of agents that target these kinases.

The oncogenic shock model may also have implications regarding the optimal strategy for treating patients with targeted inhibitors. Thus, it is possible that “pulse” treatment involving on-off cycles of drug administration, as opposed to the standard continuous treatment, could prove beneficial by providing more opportunities for the engagement of differential signal attenuation,
leading to an increased probability of oncogenic shock and hence an apoptotic outcome. However, it may prove challenging to extrapolate the kinetic findings in cell culture studies to the timing of drug administration in vivo. The oncogenic shock model may also have implications for the use of drug combinations in cancer therapy. For example, many of the commonly used cancer chemotherapy drugs inhibit cell cycle progression and, consequently, might prevent the ability of cells to undergo cell cycle-dependent apoptosis when cotreated with such agents together with inhibitors of addicting oncoproteins.

A potential role for synthetic lethality in oncogene addiction may also lead to new therapeutic strategies. Thus, the identification of addiction settings involving codependence on two different oncogene products may lead to a rational combination treatment strategy involving simultaneous disruption of both genes. In theory, the phenomenon of tumor suppressor hypersensitivity [described above] could also lead to a therapeutic opportunity in which a tumor suppressor is reintroduced into cancer cells. However, technologies enabling efficient delivery of exogenous genes to tumor cells in vivo remain a substantial challenge.

Acquired drug resistance and oncogene addiction

The phenomenon of oncogene addiction has revealed potentially important therapeutic opportunities that can lead to the selective elimination of tumor cells that exhibit strict dependence on a protein that can be targeted pharmacologically. As described above, this is well exemplified by the experience with several of the clinically approved tyrosine kinase inhibitors, including imatinib, erlotinib, and trastuzimab, which target oncogenic kinases on which tumor cells have become dependent for survival. However, an important limitation of these agents is that clinical responses, in most cases, are relatively short-lived. This is most clearly illustrated in the case of erlotinib-responsive NSCLCs, a setting in which clinical responses, even when dramatic, typically average only 6–9 mo in duration, and are almost invariably followed by disease progression (Sharma et al. 2007). Such findings appear to reflect the acquisition of drug resistance by tumor cells, and some of the molecular mechanisms underlying such resistance are beginning to be elucidated. For example, secondary kinase domain mutations that affect the so-called “gatekeeper” residue of the BCR-ABL and EGFR kinases have been identified in tumors from patients with acquired resistance to inhibitors of these kinases. These mutations confer reduced drug binding while preserving oncogenic kinase activity, thereby providing a straightforward biochemical mechanism of acquired drug resistance (Daub et al. 2004; Pao et al. 2005).

In other cases of acquired drug resistance, tumor cells may engage an alternative or redundant survival pathway (Fig. 2). For example, a recent report revealed that a subset of NSCLC patients with acquired resistance to EGFR TKIs harbor tumors that exhibit amplification of the gene encoding the MET tyrosine kinase [Engelman et al. 2007]. MET gene amplification in these cases was not detectable in the pretreatment biopsies, but was acquired during drug treatment. In these cases, it appears that MET, which can promote the activation of downstream survival pathways that overlap with those en-

**Figure 2.** Heterogeneity of tumor cell dependency as the basis for resistance to therapeutics targeting oncogene addiction. In this model, a tumor is considered to be a heterogeneous cell population comprised largely of cancer cells addicted to oncogene X (blue), but containing a small subpopulation of nonaddicted cancer cells, designated “persisters” (orange) that are characterized by very slow growth, a lack of dependency on the same survival signals as the bulk tumor population, and the ability to tolerate an initial onslaught of drug. Upon treatment with a therapeutic targeted to the addicting oncoprotein, tumor shrinkage results from ablation of the addicted cells, but persists, by virtue of the fact that they are not oncogene addicted, are maintained. These persisters have the capacity to regenerate the tumor in three distinct ways: [1] The tumor will remain composed largely of cancer cells that remain addicted to the same oncogene X (blue: *center* scenario), in which case resistance appears to be reversible, possibly involving an epigenetic mechanism; [2] the tumor is largely composed of cells that have switched their addiction to an alternative oncogene Y (green: *scenario shown on the right*); or [3] the tumor will be comprised largely of cells that exhibit coaddiction to an oncogene X in addition to the original addicting oncogene X (purple: *scenario shown on the left*).
Tumor cell heterogeneity and oncogene addiction

The examples of acquired drug resistance in cells addicted to oncogenic kinase activity described above involve stable mutational mechanisms. Presumably, such mutations are present at very low frequency within the tumor cell population—arising through random or treatment-induced mutagenesis—and are subsequently selected during drug therapy. However, acquired resistance does not necessarily require mutational mechanisms. For example, it has been reported that a subset of NSCLC patients that initially respond to treatment with EGFR TKIs and subsequently relapse can be successfully retreated with EGFR TKIs following a “drug holiday” (Kurata et al. 2004; Yano et al. 2005; Yokouchi et al. 2007; Yoshimoto et al. 2007). Such findings implicate a reversible, and presumably nongenetic mechanism by which acquired drug resistance can develop.

In this context, the distinction between drug tolerance and drug resistance in this setting merits consideration. Thus, it is possible that the ability to tolerate an initial exposure to drug involves mechanisms distinct from those that allow the cell to maintain normal proliferative and survival functions in the continued presence of drug. A reversible drug resistance mechanism might reflect the presence of a small subset of cells within the tumor population that exists in a functionally distinct state characterized by an ability to tolerate external stresses such as drug exposure. This drug-tolerant state could allow these cells to withstand an initial onslaught of stress to promote their survival for a sufficient time period to enable more stable, or even permanent resistance mechanisms to be established [Fig. 2].

Such a drug-tolerant state may be analogous to a state described for various bacterial strains following exposure to antibiotics (Balaban et al. 2004). Several studies have demonstrated the existence of antibiotic-tolerant bacterial subpopulations, known as “persisters” or “sentries,” that are able to withstand potentially toxic stresses through the engagement of epigenetic survival mechanisms (Dhar and McKinney 2007). Bacterial persisters are generally slower growing cells, and their survival within a rapidly growing population, which consists predominantly of nonpersisters, is achieved because persisters are able to revert to a nonpersistence state. Through this switching mechanism, the “burden” imposed on persisters to “protect” the population as a whole from potential eradication by external stresses is shared among the population (Lewis 2007).

An analogous stochastic switching mechanism may similarly be operative in human cancers. Thus, it is possible that a subpopulation of tumor cells with persister-like properties is present within tumors, with survival of those cells coupled to signal transduction pathways distinct from those that determine survival of the majority of tumor cells within the population [Fig. 2]. Such heterogeneity, involving a small subset of cells that can survive in the face of potentially toxic insults, may, as with antibiotic-tolerant bacteria, also be maintained via an epigenetic mechanism, and could similarly contribute to drug tolerance, followed by stable drug resistance, to ensure the long-term survival of the tumor. In this regard, it is interesting to consider the tumor cell population as a single “organism” whose survival potential is enhanced by the fact that the cells have not all coupled their survival to the same pathways. Thus, there may be heterogeneity with regard to the addicted state of the population. The nature of putative epigenetic mechanisms that might contribute to such heterogeneity among cells within a tumor population is unknown. Theoretically, it could potentially involve the up-regulation of an upstream activator of survival signaling distinct from that to which the bulk tumor cell population is addicted, although a variety of distinct mechanisms are conceivable. Such heterogeneity is somewhat reminiscent of cancer stem cells, a more slowly growing subpopulation that also appears to be maintained at low frequency within a tumor cell population and that, furthermore, has been suggested to be resistant to various anti-cancer therapies (Dean et al. 2005). Hence, persisters and cancer stem cells may constitute a single entity, both comprised of cells exhibiting survival dependencies distinct from those of the bulk tumor population.

Concluding remarks

A rapidly growing body of evidence now supports a role for oncogene addiction in the sustained survival and proliferative capacity of many if not all tumor cells. Findings from cell culture models, genetically engineered mice, and clinical testing of targeted drugs all support a widespread role for oncogene addiction in tumor cell maintenance and response to acute oncoprotein inactivation. The precise mechanism by which cells acquire dependency on a single pathway or activated protein is
not clear in most cases. Multiple theories have been put forth, including genetic streamlining, signaling network dysregulation, synthetic lethality, and oncogenic shock. However, experimental evidence to prove or disprove these models is generally lacking. Moreover, it is unlikely that a single mechanism accounts for the numerous reported experimental findings that appear to represent examples of oncogene dependency, and therefore, this still represents an important area for further investigation. Considering the potentially important therapeutic opportunity presented by oncogene addiction, there will undoubtedly be further mechanistic insights on the horizon.

References


Frisch, S.M., Vuori, K., Kelaita, D., and Sicks, S. 1996. A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and
Sharma and Settlement


Maity, A., Pare, N., Lee, J., Solomon, D., and O'Rourke, D.M.
2000. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. *Cancer Res.* **60**:5879–5886.


Yokoyama, K. and Imamoto, F. 1987. Transcriptional control of the endogenous MYC protooncogene by antisense RNA.
Oncogene addiction: setting the stage for molecularly targeted cancer therapy

Sreenath V. Sharma and Jeffrey Settleman

*Genes Dev.* 2007 21: 3214-3231
Access the most recent version at doi:10.1101/gad.1609907